

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PegBio Co., Ltd.

派格生物醫藥(杭州)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2565)

**VOLUNTARY ANNOUNCEMENT
CR059 ACCEPTED BY EASD 2026 AND SELECTED FOR
THE ORAL DISCUSSION PRESENTATION SESSION**

This announcement is made by PegBio Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis for the purpose of keeping the shareholders of the Company and potential investors informed of the latest material progress of the Group’s innovative research and development pipeline and technology platform.

The board of directors (the “**Board**”) of the Company is pleased to announce that the research results of CR059, a circular RNA-encoded GLP-1 analogue independently developed by the Group, have been accepted by the 62nd Annual Meeting of the European Association for the Study of Diabetes (European Association for the Study of Diabetes Annual Meeting 2026, “**EASD 2026**”) and selected for an oral discussion presentation session. Following the previous selection of the research results related to CR059 as a Late Breaking Abstract at the American Diabetes Association Scientific Sessions (the “**ADA Scientific Sessions**”), the acceptance by EASD 2026 and selection for an oral discussion presentation session once again mark the high level of attention and recognition received by CR059 and the Group’s circular RNA technology platform from two top-tier international academic conferences globally in the field of diabetes and metabolic diseases.

The selected research is entitled: Single-dose CR059, a circular RNA-encoded GLP-1 analogue, enables sustained exposure and prolonged body weight reduction in non-human primates. CR059 is a next-generation GLP-1 analogue developed by the Group based on its proprietary circular RNA technology platform. It is designed to enable sustained in vivo expression of a GLP-1 analogue through circular RNA encoding, thereby achieving sustained drug exposure and long-term metabolic regulation. Unlike the technical pathway of traditional peptide-based GLP-1 receptor agonists, which relies on extending drug half-life, this project explores a novel drug modality for the long-term treatment of metabolic diseases through a circular RNA-encoded expression mechanism, representing an innovative therapeutic technology direction with cutting-edge features, platform extensibility and next-generation upgrade potential.

The Company believes that the core innovative value of CR059 lies in its potential to break through the current treatment model of existing GLP-1 drugs, which are mainly administered on a weekly basis, and further expand towards ultra-long-acting treatment with monthly-or-longer and even quarterly dosing intervals. If such technical pathway is successfully translated clinically in the future, it is expected to significantly reduce the long-term medication burden of patients with chronic metabolic diseases, improve treatment compliance and long-term management efficiency, and provide a next-generation solution for obesity, type 2 diabetes and related metabolic diseases that is differentiated from existing peptide drugs.

The EASD Annual Meeting is one of the most influential international academic conferences in the field of diabetes and metabolic diseases worldwide, and together with the ADA Scientific Sessions, constitutes the most important international academic exchange platforms in this field. The oral discussion presentation is an important form of presentation granted by the EASD Annual Meeting after selection by its scientific committee, and is generally intended for research results with a high degree of innovation, scientific value and field attention. The selection of the CR059 research results for such presentation opportunity demonstrates the strong international academic appeal of the project in terms of novel drug modality, ultra-long-acting mechanism of action and potential clinical application prospects.

The Company believes that, following its selection as a Late Breaking Abstract at the ADA Scientific Sessions, the acceptance of the CR059 research results by EASD 2026 and selection for an oral discussion presentation session represent another important milestone achieved by the Group in the global research and development of next-generation innovative drugs for metabolic diseases. This progress not only reflects the cutting-edge nature and differentiated potential of the CR059 project itself, but also further validates the application value and international competitive potential of the Group's circular RNA technology platform in the direction of long-acting and ultra-long-acting treatments for metabolic diseases.

The Group has obtained approval for the launch of Visepegenatide Injection, a long-acting GLP-1 receptor agonist, and continues to deploy next-generation innovative therapies for metabolic diseases represented by CR059. The continued advancement of CR059 will help the Group further upgrade from an innovative GLP-1 drug company with an approved marketed product to an innovative metabolic disease drug company covering weekly formulations, monthly-or-longer and quarterly ultra-long-acting GLP-1 technology routes, with platform-based research and development capabilities and global academic influence. The Company believes that such progress will further enhance the Group's technical recognition, academic reputation, pipeline value and potential international collaboration opportunities in the field of global metabolic disease drug research and development.

The Group will continue to advance the research and development of CR059 and pipelines related to the circular RNA platform, and will disclose further research progress in due course, subject to compliance with applicable laws and regulations, the Listing Rules and the relevant disclosure requirements of academic conferences.

CR059 is currently still in the research and development stage, and there remain uncertainties in its subsequent clinical development, registration and approval, commercialization process and market competition landscape. The above research results do not represent that CR059 will ultimately be successfully approved for launch or commercialized. We may not be able to ultimately develop and market CR059 successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
PegBio Co., Ltd.
Michael Min XU
*Chairman of the Board, Executive Director
and General Manager*

Hong Kong, June 1, 2026

As of the date of this announcement, the Board of the Company comprises: (i) Dr. Michael Min XU and Ms. Xiaojun WANG as executive directors; (ii) Dr. Xiangjun ZHOU, Dr. Yuhong XU, Ms. Ting ZHAI and Mr. Hongkai LI as non-executive directors; and (iii) Dr. Jiancun ZHANG and Dr. Yangyang CHEN as independent non-executive directors.